TABLE OF CONTENTS

Savient Pharmaceuticals Reports Second Quarter and Year-to-Date 2007 Financial Results
	Three months ended June 30, 2007
	Six months ended June 30, 2007
	RECENT OPERATIONAL HIGHLIGHTS
	CONFERENCE CALL
	ABOUT SAVIENT PHARMACEUTICALS, INC.
	FORWARD-LOOKING LANGUAGE

Contact:	Contact:
Mary Coleman	Lippert/Heilshorn & Associates
Savient Pharmaceuticals, Inc.	Anne Marie Fields
information@savient.com	afields@lhai.com
(732) 418-9300	(212) 838-3777

Savient Pharmaceuticals Reports Second Quarter and
Year-to-Date 2007 Financial Results

EAST BRUNSWICK, N.J. — July 31, 2007 — Savient Pharmaceuticals, Inc. (NASDAQ: SVNT) today reported financial results for the three and six months ended June 30, 2007. The Company ended the second quarter with a net loss of $9.6 million, or $0.18 per basic and diluted share on total revenues of $3.1 million compared with net income of $3.2 million, or $0.05 per basic and diluted share on total revenues of $13.9 million for the same period in 2006. The company ended the quarter with $163.7 million in cash and investments.

“The second quarter of 2007 has been one of solid execution,” commented Christopher Clement, president and chief executive officer of Savient. “We continue to advance our Phase 3 clinical program for Puricase^®, which is currently being developed for the control of elevated levels of uric acid in the blood, or hyperuricemia, in patients with symptomatic gout in whom conventional treatment is contraindicated or has been shown to be ineffective. Our strong cash position continues to allow us to execute on our core objective of completing the Puricase clinical program and reporting top-line results by year-end. We remain confident of the opportunities that lie ahead with Puricase as we move forward into the second part of this year.”

Three months ended June 30, 2007

Total revenues for the second quarter of 2007 were $3.1 million, compared with $13.9 million for the second quarter of 2006, a decrease of $10.8 million due to generic competition in 2007 for Oxandrin^®, the Company’s product to promote weight gain following involuntary weight loss.

Research and development expenses for the second quarter of 2007 were $11.2 million compared with $4.2 million for the second quarter of 2006, an increase of $7.0 million. This increase was primarily due to activities related to Puricase including the Phase 3 clinical trials, the open label extension clinical trial and manufacturing validation expenses.

Selling, general and administrative expenses for the second quarter of 2007 were $7.1 million compared with $8.5 million for the second quarter of 2006, a decrease of $1.4 million. This decrease was primarily due to a reduction in Oxandrin promotional activities and termination of our Oxandrin sales force in the beginning of 2007 due to the generic competition, and a reduction in financial and financial compliance consulting activities.

The Company ended the second quarter of 2007 with $163.7 million in cash and short-term investments, decreases of $11.2 million and $15.7 million, from the prior quarter and December 31, 2006 year-end balances, respectively.

Six months ended June 30, 2007

Total revenues for the first six months of 2007 were $9.6 million, compared with $23.4 million for the same period of 2006, a decrease of $13.8 million primarily due to generic competition in 2007 for Oxandrin.

Research and development expenses for the first six months of 2007 were $24.0 million compared with $7.4 million for the same period of 2006, an increase of $16.6 million. This increase was primarily due to clinical trial expenses and manufacturing activities related to Puricase.

Selling, general and administrative expenses for the first six months of 2007 were $14.5 million compared with $19.3 million for the first six months of 2006, a decrease of $4.8 million. This decrease was primarily due to a reduction in Oxandrin promotional activities and termination of our Oxandrin sales force in the beginning of 2007 due to the generic competition, and a reduction in financial and financial compliance consulting activities.

The six-month net loss was $17.5 million or $0.33 per basic and diluted share compared with net income of $7.2 million, or $0.11 per basic and diluted share for the first six months of 2006.

RECENT OPERATIONAL HIGHLIGHTS

• Continued progress of our Puricase Phase 3 trials; administration of over 2000 infusions.

• More than half of the patients in the Phase 3 trials have completed to date.

• To date, virtually all Phase 3 completed patients have asked to enroll into the Open Label Extension program.

• Completed fill and finish operations of API bulk materials from the three validation batches, necessary to support the BLA.

• Presented two gout-related abstracts for poster presentation at the recent European League Against Rheumatism (EULAR) 2007 Annual Congress with two additional abstracts accepted for publication on-line.

CONFERENCE CALL

Savient will host a live web cast to review second quarter 2007 results on August 1, 2007 at 10:00 a.m. EST. Both the live and archived web cast can be accessed from the Investor Relations page of Savient’s website at www.savientpharma.com. A digital recording of the web cast will be available following the conclusion of the call and will be archived for thirty days. To access the recording, use the Dial-In Number and the Conference ID listed below.

Dial: (800) 642-1687 (domestic) or (706) 645-9291 (international)

Conf ID: 7348860

ABOUT SAVIENT PHARMACEUTICALS, INC.

Savient Pharmaceuticals is a biopharmaceutical company engaged in developing and distributing pharmaceutical products that target unmet medical needs in both niche and broader markets. The Company’s lead product development candidate, Puricase^® for treatment failure gout, has reported positive Phase 1 and 2 clinical data;

patient dosing in Phase 3 clinical studies began in May 2006 with patient enrollment completed in March 2007. Savient’s experienced management team is committed to advancing its pipeline and expanding its product portfolio by in-licensing late-stage compounds and exploring co-promotion and co-development opportunities that fit the Company’s expertise in specialty pharmaceuticals and biopharmaceuticals with an initial focus in rheumatology. Savient also manufactures and supplies Oxandrin^® (oxandrolone tablets, USP) CIII in the U.S. Puricase is a registered trademark of Mountain View Pharmaceuticals, Inc. Further information on Savient can be accessed by visiting: http://www.savient.com.

FORWARD-LOOKING LANGUAGE

This news release contains forward-looking statements that are subject to certain risks, trends and uncertainties that could cause actual results and achievements to differ materially from those expressed in such statements. These risks, trends and uncertainties are in some instances beyond Savient’s control. Words such as “anticipate,” “believe,” “estimate,” “expect,” “intend,” “plan,” “will” and other similar expressions help identify forward-looking statements, although not all forward-looking statements contain these identifying words. These forward-looking statements involve substantial risks and uncertainties and are based on current expectations, assumptions, estimates and projections about Savient’s business and the biopharmaceutical and specialty pharmaceutical industries in which Savient operates. Such risks and uncertainties include, but are not limited to, Savient’s stock price and market conditions, delay or failure in developing Puricase^® and other product candidates, difficulties of expanding Savient’s product portfolio through in-licensing, introduction of generic competition for Oxandrin^®, fluctuations in buying patterns of wholesalers, potential future returns of Oxandrin or other products, Savient’s continuing to incur substantial net losses for the foreseeable future, difficulties in obtaining financing, potential development of alternative technologies or more effective products by competitors, reliance on third-parties to manufacture, market and distribute many of Savient’s products, (economic, political and other risks associated with foreign operations) risks of maintaining protection for Savient’s intellectual property, risks of an adverse determination in ongoing or future intellectual property litigation, and risks associated with stringent government regulation of the biopharmaceutical industry. Savient may not actually achieve the plans, intentions or expectations disclosed in Savient’s forward-looking statements. Actual results or events could differ materially from the plans, intentions and expectations disclosed in the forward-looking statements that Savient makes. Stockholders should not place undue reliance on the forward-looking statements, which speak only as to the date of this press release. Savient’s forward-looking statements do not reflect the potential impact of any future acquisitions, mergers, dispositions, joint ventures or investments that Savient may make. Except as required by law, Savient does not assume any obligation to update any forward-looking statements.

SVNT-I

(Tables to Follow)

# # #

SAVIENT PHARMACEUTICALS, INC. AND SUBSIDIARIES
CONDENSED CONSOLIDATED BALANCE SHEETS
(Unaudited)
(in thousands, except share data)

	June 30,			December 31,
	2007			2006
Assets:
Current Assets:
Cash, cash equivalents and short-term investments	$	163,691		$	179,396
Accounts receivable, net		3,308			3,517
Notes receivable		630			644
Inventories, net		3,262			4,203
Recoverable income taxes		7,462			—
Prepaid expenses and other current assets		4,261			7,098
Total current assets		182,614			194,858
Non-current assets:
Property and equipment, net		1,531			1,139
Other assets		1,280			1,896
Total assets	$	185,425		$	197,893
Liabilities And Stockholders’ Equity:
Current Liabilities:
Accounts payable	$	2,695		$	4,552
Deferred revenue		1,309			416
Other current liabilities		12,781			15,196
Total current liabilities		16,785			20,164
Other liabilities		5,160			43
Commitments and contingencies
Stockholders’ Equity:
Preferred stock — $.01 par value 4,000,000 shares authorized; no shares issued		—			—
Common stock — $.01 par value 150,000,000 shares authorized; 53,327,000 shares issued and outstanding at June 30, 2007 and 52,309,000 shares issued and outstanding at December 31, 2006		533			523
Additional paid in capital		196,665			189,496
Accumulated deficit		(36,252	)		(14,316	)
Accumulated other comprehensive income		2,534			1,983
Total stockholders’ equity		163,480			177,686
Total liabilities and stockholders’ equity	$	185,425		$	197,893

SAVIENT PHARMACEUTICALS, INC. AND SUBSIDIARIES
CONSOLIDATED STATEMENTS OF OPERATIONS
(Unaudited)
(In thousands, except per share data)

	Three Months Ended						Six Months Ended
	June 30,						June 30,
	2007			2006			2007			2006
Revenues:
Product sales, net	$	3,098		$	13,760		$	9,479		$	23,263
Other revenues		31			100			76			100
		3,129			13,860			9,555			23,363
Cost and expenses:
Costs of goods sold		645			1,361			289			2,219
Research and development		11,194			4,166			24,018			7,414
Selling, general and administrative		7,108			8,539			14,529			19,279
Commissions and royalties		—			4			—			5
		18,947			14,070			38,836			28,917
Operating loss from continuing operations		(15,818	)		(210	)		(29,281	)		(5,554	)
Investment income		2,300			916			4,670			1,806
Other income (expense), net		(165	)		465			(331	)		8,297
Income (loss) from continuing operations before income taxes		(13,683	)		1,171			(24,942	)		4,549
Income tax expense (benefit)		(4,050	)		(35	)		(7,467	)		4
Income (loss) from continuing operations		(9,633	)		1,206			(17,475	)		4,545
Income from discontinued operations, net of income taxes		—			2,036			—			2,675
Net income (loss)	$	(9,633	)	$	3,242		$	(17,475	)	$	7,220
Earnings (loss) per common share, from continuing operations:
Basic	$	(0.18	)	$	0.02		$	(0.33	)	$	0.07
Diluted	$	(0.18	)	$	0.02		$	(0.33	)	$	0.07
Earnings per common share, from discontinued operations:
Basic	$	—		$	0.03		$	—		$	0.04
Diluted	$	—		$	0.03		$	—		$	0.04
Earnings (loss) per common share:
Basic	$	(0.18	)	$	0.05		$	(0.33	)	$	0.11
Diluted	$	(0.18	)	$	0.05		$	(0.33	)	$	0.11
Weighted average number of common and common equivalent shares:
Basic		52,419			61,358			52,209			61,286
Diluted		52,419			62,456			52,209			62,216